US Corporate Distress Financial Stress SEC Filings — September 18, 2026

18-09-2026

Cassava Sciences (ticker SAVA) disclosed on Sept 18, 2026, that its common stock failed to maintain the Nasdaq $1.00 minimum bid price for 30 consecutive business days, triggering a delisting risk. The company now has a 180-day cure period ending March 16, 2027, to regain compliance by having the closing bid price at or above $1.00 for 10 consecutive days. While the stock continues to trade under the ticker, management's ability to cure the deficiency is uncertain, and failure to comply could lead to delisting.

• · Notice received on September 17, 2026.
• · Compliance period: 180 calendar days, until March 16, 2027.
• · To regain compliance, closing bid price must be >= $1.00 for at least 10 consecutive business days.
• · If not compliant by March 16, 2027, company may qualify for a second 180-day period; otherwise Nasdaq will delist and company can appeal.
• · Stock continues to trade on Nasdaq Capital Market under symbol FLNA (in filing) – but ticker in the question is SAVA.

18-09-2026

Dillard's, Inc. (DDS, DDT) announced on September 17, 2026, its voluntary withdrawal of primary listings from the NYSE and transfer to the Texas Stock Exchange (TXSE), effective October 2, 2026 (NYSE close) and October 5, 2026 (TXSE open). The stock symbols will remain unchanged. The filing does not include any financial results or performance metrics, so no positive or negative financial trends are reported.

• · The delisting is voluntary and not due to any failure to satisfy listing standards.
• · Trading on TXSE as primary listings will begin at market open on October 5, 2026.
• · The Trust Securities include the guarantee of Dillard's, Inc.

18-09-2026

BeyondSpring Inc. (BYSI) received a Nasdaq deficiency notice on September 17, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has a 180-day compliance period until March 16, 2027, to regain compliance, and its shares continue to trade on Nasdaq in the interim. While the notification does not immediately affect business operations, there is no assurance that BeyondSpring will be able to meet the bid price requirement or other listing criteria.

• · The company may be eligible for an additional 180-day compliance period if it does not regain compliance by March 16, 2027, subject to Nasdaq staff determination.
• · The notification letter does not result in immediate delisting and has no current immediate effect on the listing or trading of the company's ordinary shares.

18-09-2026

Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days (July 31, 2026 – September 11, 2026). Because the company had effected a 1-for-25 reverse stock split on December 1, 2025, it is not eligible for the standard 180-day compliance period. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting pending the Panel's decision, but there is no assurance of continued listing.

• · The Staff Determination Letter was received on September 15, 2026, and the 8-K was filed on September 18, 2026.
• · The company is not eligible for the 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the reverse stock split within the prior one-year period.
• · The company's common stock will continue to trade on The Nasdaq Capital Market during the pendency of the hearing process.
• · The company's common stock trades under the symbol 'MBRX' on The Nasdaq Capital Market.

18-09-2026

Fusemachines Inc. (FUSE) received a Nasdaq notification on September 18, 2026, that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has a 180-day compliance period until March 17, 2027, to regain compliance by closing at or above $1.00 for at least 10 consecutive business days. If it fails, it may transfer to the Nasdaq Capital Market for an additional 180-day period, subject to meeting other listing standards.

• · The notification has no immediate effect on the listing; trading continues fully effective.
• · If compliance is not regained by March 17, 2027, the company may transfer to the Nasdaq Capital Market for an additional 180-day compliance period, provided it meets other initial listing standards and notifies Nasdaq of its intent to cure.
• · The company intends to actively monitor the bid price and evaluate options to regain compliance.

18-09-2026

InMed Pharmaceuticals received a Nasdaq deficiency notice on September 16, 2026, for failing to maintain the minimum $2.5 million shareholders' equity required for continued listing, reporting equity of only $1,075,007 as of June 30, 2026. The shortfall is largely due to transaction expenses from its planned merger with Mentari Therapeutics, which is expected to close in Q4 2026 and bring in ~$490 million in gross proceeds, potentially restoring compliance. However, the company faces significant uncertainty: it has 45 days to submit a compliance plan, and there is no assurance the plan will be accepted or that compliance will be regained, with delisting risk remaining if the merger fails to close or the plan is rejected.

• · The company's shareholders' equity decline is also attributed to costs from winding down subsidiary BayMedica, increased G&A expenses, impairment charges on intangible assets, and continued operating losses.
• · The notice has no immediate impact on trading; shares continue to trade on Nasdaq under symbol 'INM'.
• · If the compliance plan is not accepted or compliance is not regained, the company has the right to a hearing before an independent Nasdaq panel, but success is not assured.
• · The merger with Mentari is subject to shareholder approval and other conditions; the Form S-4 registration statement has been filed but not yet declared effective.

18-09-2026

Hyperfine, Inc. received a Nasdaq notice on September 17, 2026, stating that its Class A common stock has failed to maintain the minimum $1.00 bid price for 30 consecutive business days, triggering a potential delisting. The company has until March 16, 2027, to regain compliance, with a possible 180-day extension if it transfers to the Nasdaq Capital Market. While the notice does not immediately affect trading or operations, there is significant uncertainty about the company's ability to regain compliance, and a reverse stock split may be considered.

• · The company may be eligible for an additional 180-day compliance period if it transfers its listing to the Nasdaq Capital Market and meets all other initial listing standards except the bid price requirement.
• · If the company does not regain compliance by the Compliance Date, it may appeal a delisting determination to a Nasdaq Hearings Panel, but there is no assurance of success.
• · The company intends to monitor the closing bid price and consider all available options, including a potential reverse stock split.

18-09-2026

NEXTNRG, Inc. (NXXT) received a delisting notice from Nasdaq on September 15, 2026, due to failure to regain compliance with the $1.00 minimum bid price requirement by the September 14, 2026 deadline. The company is not eligible for a second 180-day compliance period because it lacks the required stockholders' equity. The company intends to request a hearing before the Nasdaq Hearings Panel by September 22, 2026, which will stay delisting pending the Panel's decision; however, there is no assurance of continued listing. The company also completed a 1-for-10 reverse stock split effective September 14, 2026, and its stock has since traded above the minimum bid price, but compliance is not guaranteed.

• · Delisting Notice received September 15, 2026; hearing request deadline September 22, 2026.
• · Reverse split (1-for-10) effective September 14, 2026; stock trading above $1.00 since then.
• · Company not eligible for second 180-day compliance period due to insufficient stockholders' equity.
• · Common stock will continue trading on Nasdaq during the appeal process, subject to Panel decision.

18-09-2026

TELA Bio, Inc. filed an 8-K on September 18, 2026, disclosing a failure to satisfy the minimum bid price requirement for continued listing on Nasdaq, triggering a potential delisting process. The company faces significant risk of being delisted if it cannot regain compliance within the applicable cure period. CEO Heather Getz signed the filing, which includes forward-looking statements about the company's ability to address the deficiency.

• · The filing is under Item 3.01 (Notice of Delisting/Failure to Satisfy a Continued Listing Rule).
• · The specific deficiency is failure to meet the Minimum Bid Price Requirement.
• · The company has a cure period to regain compliance, but failure to do so could result in delisting.
• · The filing includes standard forward-looking statements and risk factor references.